Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of IDH305 in Subjects With IDH1 Mutant Grade II or III Glioma That Has Progressed After Observation or Radiation Therapy

NCT02977689 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT02977689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02977689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of IDH305 in Subjects With IDH1 Mutant Grade II or III Glioma That Has Progressed After Observation or Radiation Therapy
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Withdrawn
Start date
April 30, 2018
Completion date
April 30, 2020
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioma